Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Zoi Zagoriti is active.

Publication


Featured researches published by Zoi Zagoriti.


Pharmacogenomics | 2011

Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase

Marianthi Georgitsi; Emmanouil Viennas; Vassiliki Gkantouna; Elena Christodoulopoulou; Zoi Zagoriti; Christina Tafrali; Fotios Ntellos; Olga Giannakopoulou; Athanassia Boulakou; Panagiota Vlahopoulou; Eva Kyriacou; John Tsaknakis; Athanassios Tsakalidis; Konstantinos Poulas; Giannis Tzimas; George P. Patrinos

AIMS Population and ethnic group-specific allele frequencies of pharmacogenomic markers are poorly documented and not systematically collected in structured data repositories. We developed the Frequency of Inherited Disorders Pharmacogenomics database (FINDbase-PGx), a separate module of the FINDbase, aiming to systematically document pharmacogenomic allele frequencies in various populations and ethnic groups worldwide. MATERIALS & METHODS We critically collected and curated 214 scientific articles reporting pharmacogenomic markers allele frequencies in various populations and ethnic groups worldwide. Subsequently, in order to host the curated data, support data visualization and data mining, we developed a website application, utilizing Microsoft™ PivotViewer software. RESULTS Curated allelic frequency data pertaining to 144 pharmacogenomic markers across 14 genes, representing approximately 87,000 individuals from 150 populations worldwide, are currently included in FINDbase-PGx. A user-friendly query interface allows for easy data querying, based on numerous content criteria, such as population, ethnic group, geographical region, gene, drug and rare allele frequency. CONCLUSION FINDbase-PGx is a comprehensive database, which, unlike other pharmacogenomic knowledgebases, fulfills the much needed requirement to systematically document pharmacogenomic allelic frequencies in various populations and ethnic groups worldwide.


Annals of clinical and translational neurology | 2014

VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis.

Nili Avidan; Rozen Le Panse; Hanne F. Harbo; Pia Bernasconi; Konstantinos Poulas; Elizabeta Ginzburg; Paola Cavalcante; Lara Colleoni; Fulvio Baggi; Carlo Antozzi; Frédérique Truffault; Shirley Horn-Saban; Simone Pöschel; Zoi Zagoriti; Angelina Maniaol; Benedicte A. Lie; Isabelle Bernard; Abdelhadi Saoudi; Zsolt Illes; Carlos Casasnovas Pons; Arthur Melms; Socrates J. Tzartos; Nicholas Willcox; Anna Kostera-Pruszczyk; Chantal Tallaksen; Renato Mantegazza; Sonia Berrih-Aknin; Ariel Miller

To identify novel genetic loci that predispose to early‐onset myasthenia gravis (EOMG) applying a two‐stage association study, exploration, and replication strategy.


BioMed Research International | 2013

Recent Advances in Genetic Predisposition of Myasthenia Gravis

Zoi Zagoriti; Manousos E. Kambouris; George P. Patrinos; Socrates J. Tzartos; Konstantinos Poulas

Myasthenia gravis (MG) is an autoimmune disease mediated by the presence of autoantibodies that bind to components of the neuromuscular junction, causing the symptoms of muscular weakness and fatigability. Like most autoimmune disorders, MG is a multifactorial, noninherited disease, though with an established genetic constituent. The heterogeneity observed in MG perplexes genetic analysis even more, as it occurs in various levels, including diverse autoantigens, thymus histopathology, and age at onset. In this context of distinct subgroups, a plethora of association studies, discussed in this review, have assessed the involvement of various HLA and non-HLA related loci in MG susceptibility, over the past five years. As expected, certain HLA alleles were strongly associated with MG. Many of the non-HLA genes, such as PTPN22 and CTLA-4, have been previously studied in MG and other autoimmune diseases and their association with MG has been reevaluated in more cohesive groups of patients. Moreover, novel risk or protective loci have been revealed, as in the case of TNIP1 and FOXP3. Although the majority of these results have been derived from candidate gene studies, the focal point of all recent genetic studies is the first genome-wide association study (GWAS) conducted on early-onset MG patients.


Clinical & Developmental Immunology | 2012

Genetics of Myasthenia Gravis: A Case-Control Association Study in the Hellenic Population

Zoi Zagoriti; Marianthi Georgitsi; Olga Giannakopoulou; Fotios Ntellos; Socrates J. Tzartos; George P. Patrinos; Konstantinos Poulas

Myasthenia gravis (MG) is an heterogeneous autoimmune disease characterized by the production of autoantibodies against proteins of the postsynaptic membrane, in the neuromuscular junction. The contribution of genetic factors to MG susceptibility has been evaluated through family and twin studies however, the precise genetic background of the disease remains elusive. We conducted a case-control association study in 101 unrelated MG patients of Hellenic origin and 101 healthy volunteers in order to assess the involvement of common genetic variants in susceptibility to MG. We focused on three candidate genes which have been clearly associated with several autoimmune diseases, aiming to investigate their potential implication in MG pathogenesis. These are interferon regulatory factor 5 (IRF-5), TNFα-induced protein 3 (TNFAIP3), also known as A20, and interleukin-10 (IL-10), key molecules in the regulation of immune function. A statistical trend of association (P = 0.068) between IL-10 promoter single nucleotide polymorphisms (SNPs) and the subgroups of early and late-onset MG patients was revealed. No statistically significant differences were observed in the rest of the variants examined. As far as we are aware, this is the first worldwide attempt to address the possible association between IRF-5 and TNFAIP3 common genetic variants and the genetic basis of MG.


PLOS ONE | 2016

Hepatic Fgf21 Expression Is Repressed after Simvastatin Treatment in Mice.

Panos G. Ziros; Zoi Zagoriti; George Lagoumintzis; Venetsana Kyriazopoulou; Ralitsa P. Iskrenova; Evagelia I. Habeos; Gerasimos P. Sykiotis; Dionysios V. Chartoumpekis; Ioannis G. Habeos

Fibroblast growth factor 21 (Fgf21) is a hormone with emerging beneficial roles in glucose and lipid homeostasis. The interest in Fgf21 as a potential antidiabetic drug and the factors that regulate its production and secretion is growing. Statins are the most widely prescribed drug for the treatment of dyslipidemia. However, the function of statins is not limited to the lowering of cholesterol as they are associated with pleiotropic actions such as antioxidant, anti-inflammatory and cytoprotective effects. The recently described effect of statins on mitochondrial function and the induction of Fgf21 by mitochondrial stress prompted us to investigate the effect of statin treatment on Fgf21 expression in the liver. To this end, C57BL6J male mice and primary mouse hepatocytes were treated with simvastatin, and Fgf21 expression was subsequently assessed by immunoblotting and quantitative real-time PCR. Hepatic Fgf21 protein and mRNA and circulating levels of FGF21significantly decreased in mice that had received simvastatin in their food (0.1% w/w) for 1 week. This effect was also observed with simvastatin doses as low as 0.01% w/w for 1 week or following 2 intraperitoneal injections within a single day. The reduction in Fgf21 mRNA levels was further verified in primary mouse hepatocytes, indicating that the effect of simvastatin is cell autonomous. In conclusion, simvastatin treatment reduced the circulating and hepatic Fgf21 levels and this effect warrants further investigation with reference to its role in metabolism.


Human Genomics | 2016

Novel genetic risk variants for pediatric celiac disease

Angeliki Balasopoulou; Biljana Stankovic; Angeliki Panagiotara; Gordana Nikcevic; Brock A. Peters; Anne John; Effrosyni Mendrinou; Apostolos Stratopoulos; Aigli Ioanna Legaki; Vasiliki Stathakopoulou; Aristoniki Tsolia; Nikolaos Govaris; Sofia Govari; Zoi Zagoriti; Konstantinos Poulas; Maria Kanariou; Nikki Constantinidou; Maro Krini; Kleopatra Spanou; Nedeljko Radlović; Bassam R. Ali; Joseph A. Borg; Radoje Drmanac; George P. Chrousos; Sonja Pavlovic; Eleftheria Roma; Branka Zukic; George P. Patrinos; Theodora Katsila

BackgroundCeliac disease is a complex chronic immune-mediated disorder of the small intestine. Today, the pathobiology of the disease is unclear, perplexing differential diagnosis, patient stratification, and decision-making in the clinic.MethodsHerein, we adopted a next-generation sequencing approach in a celiac disease trio of Greek descent to identify all genomic variants with the potential of celiac disease predisposition.ResultsAnalysis revealed six genomic variants of prime interest: SLC9A4 c.1919G>A, KIAA1109 c.2933T>C and c.4268_4269delCCinsTA, HoxB6 c.668C>A, HoxD12 c.418G>A, and NCK2 c.745_746delAAinsG, from which NCK2 c.745_746delAAinsG is novel. Data validation in pediatric celiac disease patients of Greek (n = 109) and Serbian (n = 73) descent and their healthy counterparts (n = 111 and n = 32, respectively) indicated that HoxD12 c.418G>A is more prevalent in celiac disease patients in the Serbian population (P < 0.01), while NCK2 c.745_746delAAinsG is less prevalent in celiac disease patients rather than healthy individuals of Greek descent (P = 0.03). SLC9A4 c.1919G>A and KIAA1109 c.2933T>C and c.4268_4269delCCinsTA were more abundant in patients; nevertheless, they failed to show statistical significance.ConclusionsThe next-generation sequencing-based family genomics approach described herein may serve as a paradigm towards the identification of novel functional variants with the aim of understanding complex disease pathobiology.


Journal of Neuroimmunology | 2018

Evidence for association of STAT4 and IL12RB2 variants with Myasthenia gravis susceptibility: What is the effect on gene expression in thymus?

Zoi Zagoriti; George Lagoumintzis; Gianluca Perroni; George Papathanasiou; Andreas Papadakis; Vincenzo Ambrogi; Tommaso Claudio Mineo; John Tzartos; Konstantinos Poulas

Myasthenia gravis (MG) is an autoimmune disease mediated by the presence of autoantibodies that bind mainly to the acetylcholine receptor (AChR) in the neuromuscular junction. In our case-control association study, we analyzed common variants located in genes of the IL12/STAT4 and IL10/STAT3 signaling pathways. A total of 175 sporadic MG patients of Greek descent, positively detected with anti-AChR autoantibodies and 84 ethnically-matched, healthy volunteers were enrolled in the study. Thymus samples were obtained from 16 non-MG individuals for relative gene expression analysis. The strongest signals of association were observed in the cases of rs6679356 between the late-onset MG patients and controls and rs7574865 between early-onset MG and controls. Our investigation of the correlation between the MG-associated variants and the expression levels of each gene in thymus did not result in significant differences.


Human Genomics | 2015

Identification of cancer predisposition variants in apparently healthy individuals using a next-generation sequencing-based family genomics approach

Ioannis Karageorgos; Clint Mizzi; Efstathia Giannopoulou; Cristiana Pavlidis; Brock A. Peters; Zoi Zagoriti; Peter D. Stenson; Konstantinos Mitropoulos; Joseph A. Borg; Haralabos P. Kalofonos; Radoje Drmanac; Andrew Stubbs; Peter J. van der Spek; David Neil Cooper; Theodora Katsila; George P. Patrinos


Annual research & review in biology | 2014

From therapeutic Electrotherapy to Electroceuticals: Formats, Applications and Prospects of Electrostimulation

Manousos E. Kambouris; Zoi Zagoriti; George Lagoumintzis; Konstantinos Poulas


Food and Chemical Toxicology | 2018

Tobacco-specific nitrosamines: A literature review

Evangelia Konstantinou; Foteini Fotopoulou; Athanasios Drosos; Nektaria Dimakopoulou; Zoi Zagoriti; Athanasios Niarchos; Dimitra Makrynioti; Dimitrios Kouretas; Konstantinos E. Farsalinos; George Lagoumintzis; Konstantinos Poulas

Collaboration


Dive into the Zoi Zagoriti's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Brock A. Peters

Howard Hughes Medical Institute

View shared research outputs
Researchain Logo
Decentralizing Knowledge